Pfizer Inc. (PFE) ELREXFIO Meets Phase 3 PFS Goal vs SOC in RRMM

What happened

Pfizer said its Phase 3 MagnetisMM-32 trial met its primary endpoint, with ELREXFIO monotherapy reducing the risk of progression or death versus three standard regimens in RRMM, showing 68% progression-free survival at 18 months.

Confirmed

Global impact / market context

A win against three active standard regimens could help ELREXFIO move into earlier treatment settings, where more patients may receive it, supporting future Pfizer revenue if regulators approve planned filings.

Analyst inference

Investors weigh this efficacy signal against immature overall survival data. Clear survival benefit and timely approvals would strengthen the commercial case, while delays or weak survival results could limit how much revenue the drug adds.

Analyst inference

What to watch

1. Pfizer plans regulatory submissions for ELREXFIO based on the MagnetisMM-32 results, which could create near-term filing and approval catalysts for the drug. Confirmed
2. Watch for maturing overall survival data, because a clear survival benefit would support broader use and physician adoption beyond the progression-free survival result. Analyst inference
3. Track whether regulators accept the filings and expand ELREXFIO's label toward earlier RRMM settings, which would widen the patient group eligible for treatment. Proposed

Evidence

• Original source link unavailable